Werewolf Therapeutics (HOWL) EBITDA (2020 - 2026)

Werewolf Therapeutics (HOWL) has reported EBITDA for 7 consecutive years, with $7.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 140.8% year-over-year to $7.2 million in Q2 2026; TTM through Jun 2026 was -$31.3 million, a 57.19% increase from a year earlier, with the FY2025 full-year figure at -$60.7 million, up 17.55% from the prior year.
• EBITDA was $7.2 million for Q2 2026 at Werewolf Therapeutics, up from -$13.3 million in the prior quarter.
• Over five years, EBITDA peaked at $7.2 million in Q2 2026 and troughed at -$20.3 million in Q4 2024.
• A 5-year average of -$13.2 million and a median of -$14.1 million in 2022 frame the typical range for EBITDA.
• Across the five-year window, EBITDA plunged 212.51% in 2024 and surged 140.8% in 2026, its largest moves.
• Over 5 years, EBITDA stood at -$13.2 million in 2022, then rose by 1.65% to -$13.0 million in 2023, then slumped by 56.98% to -$20.3 million in 2024, then surged by 53.72% to -$9.4 million in 2025, then surged by 176.0% to $7.2 million in 2026.
• The last three EBITDA figures came in at $7.2 million (Q2 2026), -$13.3 million (Q1 2026), and -$9.4 million (Q4 2025), per Business Quant data.